| Literature DB >> 26877646 |
Abstract
The study aimed to evaluate the effect of kefir combination from goat milk and soy milk on lipid profile, plasma glucose, glutathione peroxidase (GPx) activity and the improvement of pancreatic β-cell in diabetic rats. Male rats were divided into five treatments: normal control, diabetic control, goat milk kefir, combination of goat milk-soy milk kefir and soy milk kefir. All rats were induced by streptooztocin-nicotinamide (STZ-NA), except for normal control. After 35 d experiment, the rats were sampled for blood, sacrificed and sampled for pancreatic tissues. Results showed that diabetic rats fed kefir combination had higher (p<0.05) triglyceride than the rats fed goat milk or soy milk kefir. Decreasing of plasma glucose in diabetic rats fed kefir combination was higher (p<0.05) than rats fed goat millk kefir. The activity of GPx in diabetic rats fed three kinds of kefir were higher (p<0.01) than untreated diabetic rats. The average number of Langerhans and β-cells in diabetic rats fed kefir combination was the same as the normal control, but it was higher than diabetic control. It was concluded that kefir combination can be used as antidiabetic through maintaining in serum triglyceride, decreasing in plasma glucose, increasing in GPx activity and improving in pancreatic β-cells.Entities:
Keywords: glutathione peroxidase; kefir combination; lipid profile; plasma glucose; β-cells
Year: 2015 PMID: 26877646 PMCID: PMC4726966 DOI: 10.5851/kosfa.2015.35.6.847
Source DB: PubMed Journal: Korean J Food Sci Anim Resour ISSN: 1225-8563 Impact factor: 2.622
The average of antioxidant actvity (DPPH-scavenging) of milk and kefir
| Milk and kefir | DPPH scavenging (%) |
|---|---|
| Goat milk | 1.01±1.75a |
| Soy milk | 10.71±1.13d |
| Goat milk Kefir | 5.52±0.99bc |
| Goat milk : soy milk (75:25) kefir | 3.70±2.33ab |
| Goat milk : soy milk (50:50) kefir | 6.67±2.33bc |
| Goat milk : soy milk (25:75) kefir | 7.74±3.29cd |
| Soy milk Kefir | 8.08±1.23cd |
Different letters (a, b) in the column indicated significant difference (p<0.01).
The average body weight of rats with different treatment
| Perlakuan | Body weight (g) | |
|---|---|---|
| Pre- treatment | Post- treatment | |
| Normal control | 279.60±18.66a | 358.60±13.97b |
| Diabetic control | 212.00±41.76a | 198.60±75.20a |
| Diabetic + goat milk kefir | 217.00±33.56a | 231.60±78.19a |
| Diabetic + goat-soy milk kefir | 257.20±33.60a | 268.20±40.11a |
| Diabetic + soy milk kefir | 221.60±47.69a | 195.80±86.25a |
Different letters (a, b) in the same row indicated significant difference (p<0.05).
Lipids profile in rats with different treatments
| Lipid | Treatment | ||||
|---|---|---|---|---|---|
| Normal control | Diabetic control | Diabetic+Goat milk kefir | Diabetic+Goat-soy milk kefir | Diabetic+Soy milk kefir | |
| Triglyceride (mg/dL) | |||||
| Pre-test | 112.98±54.49a | 70.74±27.73a | 75.33±35.93a | 67.21±25.37a | 98.96±83.84a |
| Post-test | 174.97±7.51a | 50.80±21.78b | 66.34±37.64bc | 89.43±28.74c | 63.08±30.97bc |
| Delta* | 61.98±38.49a | −19.94±30.33b | −8.98±24.13b | 22.21±32.37ab | −35.88±67.02b |
| p pre-post** | 0.011 | 0.216 | 0.678 | 0.154 | 0.345 |
| Total Cholesterol (mg/dL) | |||||
| Pre-test | 49.25±12.09a | 57.46±12.87a | 62.61±21.01a | 43.93±6.36a | 49.58±14.37a |
| Post-test | 45.0±17.37a | 44.96±17.29ab | 61.66±11.30b | 51.00±2.90ab | 50.36±15.16ab |
| Delta* | −4.23±11.46ab | −12.50±12.26a | −0.94±27.67ab | 7.06±5.27b | 0.78±10.07ab |
| p pre-post** | 0.463 | 0.085 | 0.859 | 0.028 | 0.600 |
| LDL (mg/dL) | |||||
| Pre-test | 15.68±8.36a | 22.92±5.88ab | 25.85±8.48b | 19.70±8.69ab | 17.66±4.07ab |
| Post-test | 13.91±4.04a | 18.20±6.22ab | 23.13±8.43b | 20.23±7.71ab | 20.46±5.21ab |
| Delta* | −1.76±8.41a | −4.72±6.89a | −2.72±12.87a | 0.53±13.44a | 2.80±1.90a |
| p pre-post** | 0.629 | 0.225 | 0.544 | 0.926 | 0.016 |
| HDL (mg/dL) | |||||
| Pre-test | 37.50±8.88a | 37.48±9.37a | 38.04±10.16a | 34.01±4.57a | 34.06±16.68a |
| Post-test | 22.70±6.54a | 28.70±7.71ab | 43.64±21.17b | 25.95±2.31ab | 32.45±14.07ab |
| Delta* | −14.80±10.57a | −8.78±12.82a | 5.60±26.05a | −8.06±6.08a | −1.61±25.37a |
| p pre-post** | 0.016 | 0.200 | 0.678 | 0.023 | 0.882 |
Different letters (a, b) in the same row indicated significant difference (p<0.05).
*Delta value (difference mean between pre test-post test): positive number indicated an increase, and negative indicated a decrease.
**p<0.05 in each column indicated significant difference between pre and post-test.
The average of plasma glucose levels of rats with different treatment
| Treatment groups | Plasma glucose (mg/dL) | ||
|---|---|---|---|
| Pre-treatment | Post-treatment | Delta pre-post | |
| Normal control | 73.67±12.77 | 116.86±8.85 | 43.18±4.95 |
| Diabetic control | 283.11±140.01 | 379.72±83.97 | 96.61±111.51a |
| Diabetic + goat milk kefir | 220.06±97.50 | 127.70±46.06 | −92.36±116.05a |
| Diabetic + goat-soy milk kefir | 338.41±41.74 | 112.46±11.11 | −225.95±36.71b |
| Diabetic + soy milk kefir | 391.24±146.57 | 257.38±175.16 | −133.85±172.37b |
Different letters (a, b) in the same column indicated significant difference (p<0.05).
The average of glutathione peroxidase (GPx) in rats with different treatment
| Treatment groups | GPx activity (nmol/mL/min) |
|---|---|
| Normal control | 0.133±0.00a |
| Diabetic control | 0.013±0.00b |
| Diabetic + goat milk kefir | 0.120±0.01a |
| Diabetic + goat-soy milk kefir | 0.116±0.02a |
| Diabetic + soy milk kefir | 0.094±0.03a |
Different letters (a, b) in the column indicated significant difference (p<0.01).
The average number of Langerhans and β-cells in rats with different treatment
| Treatment groups | Langerhans | Beta cells |
|---|---|---|
| Normal control | 2.60±0.32a | 61.29±16.26a |
| Diabetic control | 1.16±0.28b | 2.58 ±1.23b |
| Diabetic + goat milk kefir | 2.27±1.05ab | 15.03±7.70bc |
| Diabetic + goat-soy milk kefir | 3.23±0.53a | 66.55±20.69a |
| Diabetic + soy milk kefir | 3.10±1.45a | 29.73±28.07c |
Different letter (a, b, c) in the same column indicate significant difference, for Langerhans (p<0.05), and for β-cells (p<0.01).
Fig. 1.Victoria-blue stained sections for pancreatic β-cells (showed blue-stained in cytoplasm). A) normal rats; B) untreated diabetic rats; C, D & E) diabetic rats treated with goat milk kefir, combination of goat milk-soy milk kefir and soy milk kefir, respectively. Magnification 100 and 400x.